Baxter Healthcare recalled 5,209 oral probes on September 17, 2025. The probes were incorrectly programmed to show lower temperatures, risking delayed treatment for fever-related symptoms. Consumers and healthcare providers must stop using the affected probes immediately.
Affected oral/axillary probes were inadvertently programmed with the rectal probe configuration. Affected probes will potentially display a lower temperature than the true value, which may lead to a delay in managing fever-related symptoms or infection.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Baxter Healthcare Corporation or your healthcare provider for instructions. Notification method: Letter
The recall involves oral probes (Product code 02893-000) used with Welch Allyn SureTemp Plus 690 (Product codes 01690-200 and 01690-400) and Welch Allyn SureTemp Plus 692 (01692-200) thermometers. The affected products were distributed nationwide in the U.S., Canada, and Colombia.
Affected oral/axillary probes were mistakenly programmed with a rectal probe configuration. This error can lead to inaccurate temperature readings, potentially delaying the management of fever-related symptoms or infections.
There have been no reported injuries or fatalities associated with this recall. The high hazard classification indicates a significant risk of misdiagnosis.
Stop using the affected probes immediately. Patients and healthcare providers should follow recall instructions provided by Baxter Healthcare.
For more information, contact Baxter Healthcare Corporation. Visit the FDA recall page for further details.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.